- Home
- SLG vs GH Comparison
SLG vs GH Comparison
Compare SLG & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLG
- GH
- Stock Information
- Founded
- SLG 1980
- GH 2011
- Country
- SLG United States
- GH United States
- Employees
- SLG 1188
- GH N/A
- Industry
- SLG Real Estate Investment Trusts
- GH Medical Specialities
- Sector
- SLG Real Estate
- GH Health Care
- Exchange
- SLG Nasdaq
- GH Nasdaq
- Market Cap
- SLG 4.5B
- GH 4.3B
- IPO Year
- SLG 1997
- GH 2018
- Fundamental
- Price
- SLG $65.44
- GH $38.75
- Analyst Decision
- SLG Hold
- GH Strong Buy
- Analyst Count
- SLG 16
- GH 14
- Target Price
- SLG $68.38
- GH $39.93
- AVG Volume (30 Days)
- SLG 918.2K
- GH 1.8M
- Earning Date
- SLG 01-22-2025
- GH 02-20-2025
- Dividend Yield
- SLG 4.91%
- GH N/A
- EPS Growth
- SLG N/A
- GH N/A
- EPS
- SLG N/A
- GH N/A
- Revenue
- SLG $920,135,000.00
- GH $692,256,000.00
- Revenue This Year
- SLG N/A
- GH $32.21
- Revenue Next Year
- SLG $4.08
- GH $16.90
- P/E Ratio
- SLG N/A
- GH N/A
- Revenue Growth
- SLG N/A
- GH 29.20
- 52 Week Low
- SLG $41.81
- GH $15.81
- 52 Week High
- SLG $82.81
- GH $39.29
- Technical
- Relative Strength Index (RSI)
- SLG 32.79
- GH 70.24
- Support Level
- SLG $60.35
- GH $34.80
- Resistance Level
- SLG $69.66
- GH $39.29
- Average True Range (ATR)
- SLG 1.84
- GH 1.78
- MACD
- SLG -0.35
- GH 0.56
- Stochastic Oscillator
- SLG 31.90
- GH 94.19
About SLG SL Green Realty Corp
SL Green Realty is one of the largest Manhattan property owners and landlords, with interest in around 32 million square feet of wholly owned and joint-venture office space. The company has additional property exposure through its limited portfolio of well-located retail space. It operates as a real estate investment trust.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.